Pulmonary Arterial Hypertension

The AJMC^® Pulmonary Arterial Hypertension compendium is a comprehensive resource for clinical news and expert insights for the progressive disorder, which is characterized by high blood pressure in the arteries that go from the heart to the lungs.

Latest News

June 11th 2025

TPIP a Potential Game-Changer for Prostanoid Therapy in PAH

By Victoria Johnson

June 4th 2025

New Insights Into Meth-Associated PAH Care Gaps: Anjali Vaidya, MD, on Closing the Divide

By Maggie L. Shaw
Anjali Vaidya, MD, FACC, FASE, FACP

May 30th 2025

Sotatercept for PAH Maintains Safety, Reduced Mortality in Long-Term Follow-Up

By Hayden E. Klein

May 28th 2025

Suboptimal Care for PAH Persists Among Women

By Maggie L. Shaw

May 15th 2025

Impedance Cardiography Offers Noninvasive Insight Into PAH Progression

By Maggie L. Shaw

Transforming PAH Management Through Innovation and Strategic Care

Learn how novel therapies, early diagnosis, and personalized treatment approaches are advancing PAH care while addressing clinical needs, patient preferences, and economic impact.

Watch the Series

Video Interviews

March 31st 2025

ZENITH Trial Findings Could Reshape PAH Treatment, Extending Sotatercept’s Reach

June 12th 2024

Addressing Unmet Needs in the PAH Landscape

June 12th 2024

Optimizing PAH Care Delivery for Better Outcomes

June 5th 2024

Advancing Pulmonary Arterial Hypertension Care: Overcoming Challenges in Special Populations and Exploring Innovative Approaches

May 29th 2024

Overcoming Barriers to Better Patient Outcomes in PAH

May 22nd 2024

FDA Approves Sotatercept for Pulmonary Arterial Hypertension

May 15th 2024

Optimizing Complex Pulmonary Arterial Hypertension Care: Enhancing Adherence and Outcomes

A New Era in PAH Treatment?

Breaking Down the PAH Cost Burden

Overcoming Limitations and Barriers Associated with Treating Pulmonary Arterial Hypertension

More News

Walking analysis | Image Credit: © Microgen-stock.adobe.com

May 6th 2025

18MWT Contributes Valuable Feedback in Setting of PAH

The 18-meter walk test (18MWT) effectively evaluates disease severity and predicts clinical outcomes in pulmonary arterial hypertension (PAH), enhancing traditional assessment methods.

Doctor holding generated image of lungs inside a heart | Image credit: Kiattisak - stock.adobe.com

April 28th 2025

PH, PAH Prevalence Higher in Medicaid, With Racial, Ethnic Disparities

Laura Joszt, MA

Medicaid beneficiaries face higher rates of pulmonary hypertension, with significant economic burdens and racial disparities in prevalence and costs.

Fitness device | Image Credit: © anatolir-stock.adobe.com

April 21st 2025

Wearable Tech Has Potential to Indicate PAH-Related Decline

For this analysis, outcomes were compared between individuals who had pulmonary arterial hypertension (PAH) and healthy controls by using Fitbit-derived data over 12 weeks and then at a 1-year follow-up.

Blood pressure graphic | Image Credit: © Dzianis Vasilyeu-stock.adobe.com

April 8th 2025

Worse CTD-PAH Prognosis Seen With Higher HFA-PEFF Score

The findings from this single-center retrospective study compare outcomes between 2 groups of patients living with connective tissue disease–associated pulmonary arterial hypertension (CTD-PAH) stratified by their Heart Failure Association–preserved ejection fraction (HFA-PEFF) algorithm score.

PAH | Image Credit: © Richelle-stock.adobe.com

April 4th 2025

Burden of PAH Weighs Heavy Worldwide

Three decades of data from the Global Burden of Disease Study were analyzed for trends in global, regional, and national burdens in pulmonary arterial hypertension (PAH).

Glass pharmaceutical vials | Image credit: ronnarong – stock.adobe.com

March 31st 2025

Sotatercept Reduces Risk of Death, Transplant, or Hospitalization in Advanced PAH

Hayden E. Klein

Patients taking sotatercept had a 76% relative risk reduction in morbidity and mortality events compared with patients taking placebo.

Pulmonary hypertension | Image Credit: © Uladzislau-stock.adobe.com

March 26th 2025

PAH Therapies Improve Outcomes in PH-ILD

Pulmonary hypertension is a common consequence of interstitial lung disease (PH-ILD), with the highest rate seen among individuals who have idiopathic pulmonary fibrosis. Overall, most cases of PH in the setting of ILD are mild.

Hypertension | Image Credit: © jeffy1139-stock.adobe.com

March 24th 2025

Lorundrostat Significantly Lowers Blood Pressure in Key Hypertension Trials

New topline data from the Launch-HTN (NCT06153693) and Advance-HTN (NCT06153693) clinical trials show these investigations met their primary end points os statistically significant reductions in systolic blood pressure.

Patients with PAH had distinct PA flow characteristics compared with those with PH-HFpEF. | Image credit: Thirawat - stock.adobe.com

March 21st 2025

Pulmonary Hypertension Subtypes Show Distinct PA Flow Hemodynamics

Jared Kaltwasser

Investigators used 4D flow cardiovascular magnetic resonance imaging to search for differences between pulmonary artery (PA) remodeling in pulmonary arterial hypertension and other types of pulmonary hypertension.

Measuring BP in pregnancy | Image Credit: ©Mediteraneo-stock.adobe.com

March 18th 2025

Managing Pulmonary Hypertension in Pregnancy

Pulmonary arterial hypertension (PAH) can be a challenging complication to manage during pregnancy; women with PAH who are pregnant are considered a high-risk population, and they face higher rates of maternal and fetal complications.

Congenital heart disease | Image Credit: © ibreakstock-stock.adobe.com

March 14th 2025

PAH Treatment Benefits Extend to Patients With Repaired Congenital Heart Disease

Historical data show the prevalence of pulmonary arterial hypertension (PAH) in adult patients with congenital heart disease ranges from 4% to 28%, according to studies from the US and Europe—and that the prevalence of these comorbid condition is on the rise.

Hyperuricemia may be an important risk factor for pulmonary arterial hypertension. | Image credit: jarun011 - stock.adobe.com

January 3rd 2025

High Uric Acid Appears to Have Causal Role in PAH

Jared Kaltwasser

A Mendelian analysis supports the idea that hyperuricemia may be an important risk factor for pulmonary arterial hypertension (PAH).

A new report suggests that patients with PAH consistently report higher symptom burden than their physicians do for their condition | image credit: bongkarn - stock.adobe.com

December 30th 2024

People With PAH Report Higher Symptom Burden Than Their Physicians

Jared Kaltwasser

Patients and physicians agree about which symptoms have the biggest impact on patients’ quality of life.

Top 5 PAH Articles of 2024

December 29th 2024

Top 5 Most-Read PAH Articles of 2024

Julia Bonavitacola

The top articles about pulmonary arterial hypertension (PAH) in 2024 included FDA approvals, the effect of salt substitutes on hypertension, and how diagnosis time affects outcomes.

Heart | Image credit: appledesign - stock.adobe.com

December 19th 2024

Researchers Characterize Limitations With Methods of Determining IVS Flattening in PH

AJMC Contributor

Based on their findings, the researchers suggest the integration of automated measures to identify interventricular septal (IVS) flattening in these patients.

PAH | Image Credit: © Kiattisak-stock.adobe.com

December 12th 2024

New Study Evaluates Quality-of-Life Instruments for Patients With PAH

Kimberly Rath, PharmD

A systematic review of quality-of-life tools available specifically for pulmonary arterial hypertension (PAH) reveals that although several instruments demonstrate strong psychometric properties and reliability, significant gaps remain in these tools' validation and methodological rigor.

Lung analysis concept | image credit: Shahidah - stock.adobe.com

December 8th 2024

Nanoparticle Delivery Holds Promise for Treatment of PAH

Karen Jacobson-Sive

Aerosolized vascular endothelial growth factor/stromal cell-derived factor-1α (VEGFNP/SDFNP) led to a lower pulmonary arterial pressure and prevented right ventricular hypertrophy after monocrotaline (MCT) injection in rats.

Chest X-ray for lung health assessment | image credit: Radiographys - stock.adobe.com

December 5th 2024

Slow, Steady Advances: Noninvasive Diagnosis of PH in ILD Populations

Gayle Turim Dickstein

Many roadblocks exist to detecting and assessing pulmonary hypertension (PH) in patients with interstitial lung disease (ILD), but creative thinking and artificial intelligence (AI) may soon help improve the landscape.

patient taking pills | Image Credit: © fizkes - stock.adobe.com

November 24th 2024

Communication Can Boost Medication Persistence in PAH

Jared Kaltwasser

Patients continued taking their medications for pulmonary arterial hypertension (PAH) when symptoms appeared to improve, according to a new survey.

Doctor with hands holding an image of lungs | Image credit: Orawan - stock.adobe.com

November 20th 2024

Why Right Heart Catheterization Confirming PAH Diagnosis May Be Underperformed

Gayle Turim Dickstein

Professional guidelines say that when pulmonary arterial hypertension (PAH) is diagnosed, right heart catheterization should be performed, but a quarter of the time, it isn’t—so investigators set out to discover why.

Patients with PAH may experience issues with sleep | image credit: princeoflove - stock.adobe.com

November 14th 2024

Poor Sleep Quality Associated With Pulmonary Arterial Hypertension

Karen Jacobson-Sive

Most patients with pulmonary arterial hypertension (PAH) suffered from poor sleep quality, and dyspnea was a significant predictor of sleep quality, independent of disease severity, according to this study.

patient and doctor - Halfpoint - stock.adobe.com.jpeg

November 6th 2024

Refinements to European Strategy Can Improve PAH-CHD Stratification

AJMC Contributor

When patients were re-classified based on the adjusted thresholds of N-terminal pro-brain natriuretic peptide and 6-minute walk distance and the inclusion of TAPSE rather than right atria area, classification of patients improved significantly.

Pulmonary hypertension | Image Credit: © Designpics - stock.adobe.com

November 1st 2024

PAH Treatment Outcomes Similar Regardless of Diagnosis Time

AJMC Contributor

The study findings underscore the importance of early initiation of macitentan and tadalafil among patients who have pulmonary arterial hypertension (PAH), and represent a shift in understanding of prognosis based on diagnosis timing.

PAH concept | image credit: Ahmad - stock.adobe.com

October 23rd 2024

Early Use of Triple Oral Therapy May Lower Hospitalizations for PAH

AJMC Contributor

The comparative effectiveness study found that the addition of selexipag (Uptravi) to double oral therapy (DOT) reduced the risk of patients being hospitalized or having their disease progress.

Doctor holds lung model representing PAH | Image Credit: © Orawan - stock.adobe.com

October 16th 2024

Certain Immune Cells May Increase, Decrease PAH Risk

Gayle Turim Dickstein

Using Mendelian randomization analysis, researchers found evidence that 2 small groups of immunophenotypes are linked to either greater or lesser odds of developing pulmonary arterial hypertension (PAH).

Mobility reduction may be an early sign of PAH | image credit: PrusarooYakk - stock.adobe.com

October 9th 2024

A Call for Consistent Digital Mobility Measurement Protocols in PAH

Gayle Turim Dickstein

As more researchers utilize digital technology to measure mobility in pulmonary arterial hypertension (PAH), a team calls for consistent protocols to make outcomes as meaningful as possible to patients and clinicians

Carboard cutout of lungs with a stethoscope and the words Pulmonary Hypertension | Image credit: Dzmitry - stock.adobe.com

October 4th 2024

Complementary Therapies Improve Quality of Life in PH

Initial evidence suggests alternative approaches such as exercise, dietary modification, and psychosocial therapies may enhance traditional management of pulmonary hypertension.

Human lungs on scientific background | Image Credit: © Crystal light - stock.adobe.com

September 27th 2024

Combined Chemotherapy and Immunotherapy Improves Outcomes in PAH

An adult patient with pulmonary arterial hypertension (PAH) and metastatic lung adenocarcinoma showed significant clinical improvement when chemotherapy and immunotherapy were added to PAH triple therapy.

Man holding paper model of lungs | Image credit: Elena - stock.adobe.com

September 20th 2024

Comorbidities Require Special Treatment Consideration for PAH

AJMC Contributor

In addition to being diagnosed more frequently in older patients, pulmonary arterial hypertension (PAH) is more frequently diagnosed in patients with cardio-pulmonary comorbidities, which poses challenges to the optimal treatment of PAH, explained the researchers.

Months after the FDA's approval of sotatercept for treating PAH, the drug has gained European approval | image credit: wladimir1804 - stock.adobe.com

September 11th 2024

Sotatercept Gains European Approval for PAH for Use With Other Treatments

AJMC Contributor

The European approval comes months after the FDA’s approval of the first-of-its-kind treatment for pulmonary arterial hypertension (PAH).

1 2 3 4 5 6 7 8

...

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions